AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic506
  • Dermatology157
  • Gastroenterology & Hepatology173
  • Hematology29
  • Immunology149
  • Infectious Disease118
  • Nephrology108
  • Neurology466
  • Oncology1,082
  • Ophthalmology40
  • Psychiatry141
  • Rare & Genetic Diseases49
  • Respiratory140
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic506
  • Dermatology157
  • Gastroenterology & Hepatology173
  • Hematology29
  • Immunology149
  • Infectious Disease118
  • Nephrology108
  • Neurology466
  • Oncology1,082
  • Ophthalmology40
  • Psychiatry141
  • Rare & Genetic Diseases49
  • Respiratory140
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access Guide

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

Calendar

Upcoming trial readouts

Estimated primary-completion dates sourced from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates: they can and do move as trials progress.

Events

Company

867 more; type to narrow.

3037 upcoming events

October 2026 (50)
Xanomeline/trospium chloride · CobenfyPhase 3
Est. primary completion 2026-10-05 · Bristol-Myers Squibb · Alzheimer's Disease
NCT05511363 · CT.gov ↗
What to watch
dupilumab · DupixentPhase 3
Est. primary completion 2026-10-07 · Regeneron Pharmaceuticals + Sanofi · Atopic Dermatitis
NCT02612454 · CT.gov ↗
What to watch
RuxolitinibPhase 3
Est. primary completion 2026-10-09 · Incyte · Hidradenitis Suppurativa
NCT06958211 · CT.gov ↗
What to watch
RuxolitinibPhase 3
Est. primary completion 2026-10-09 · Incyte · Hidradenitis Suppurativa
NCT06959225 · CT.gov ↗
What to watch
HDM1002Phase 3
Est. primary completion 2026-10-10 · Hangzhou Zhongmei Huadong Pharmaceutical · Type 2 Diabetes
NCT07193459 · CT.gov ↗
What to watch
Ravulizumab · UltomirisPhase 3
Est. primary completion 2026-10-12 · AstraZeneca · Paroxysmal Nocturnal Hemoglobinuria
NCT05133531 · CT.gov ↗
What to watch
Eculizumab · SolirisPhase 3
Est. primary completion 2026-10-12 · Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) · Paroxysmal Nocturnal Hemoglobinuria
NCT05133531 · CT.gov ↗
What to watch
PozelimabPhase 3
Est. primary completion 2026-10-12 · Regeneron Pharmaceuticals · Paroxysmal Nocturnal Hemoglobinuria
NCT05133531 · CT.gov ↗
What to watch
CemdisiranPhase 3
Est. primary completion 2026-10-12 · Alnylam Pharmaceuticals + Regeneron Pharmaceuticals · Paroxysmal Nocturnal Hemoglobinuria
NCT05133531 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2026-10-12 · AstraZeneca · AMI, STEMI, NSTEMI, Left Ventricular Dysfunction
NCT05764057 · CT.gov ↗
What to watch
JSKN003Phase 3
Est. primary completion 2026-10-13 · Alphamab Oncology + CSPC Pharmaceutical Group · Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
NCT06846437 · CT.gov ↗
What to watch
itepekimabPhase 3
Est. primary completion 2026-10-14 · Regeneron Pharmaceuticals + Sanofi · Chronic Rhinosinusitis With Nasal Polyps
NCT06834347 · CT.gov ↗
What to watch
AtezolizumabPhase 3
Est. primary completion 2026-10-14 · Roche · Unresectable Hepatocellular Carcinoma
NCT04770896 · CT.gov ↗
ApatinibPhase 3
Est. primary completion 2026-10-15 · Jiangsu Hengrui Pharmaceuticals · Neoadjuvant Therapy
NCT06913777 · CT.gov ↗
What to watch
FamitinibPhase 3
Est. primary completion 2026-10-15 · Jiangsu Hengrui Pharmaceuticals · Neoadjuvant Therapy
NCT06913777 · CT.gov ↗
What to watch
AdebrelimabPhase 3
Est. primary completion 2026-10-15 · Jiangsu Hengrui Pharmaceuticals · Neoadjuvant Therapy
NCT06913777 · CT.gov ↗
What to watch
deucravacitinib · SotyktuPhase 3
Est. primary completion 2026-10-19 · Bristol-Myers Squibb · Systemic Lupus Erythematosus
NCT05617677 · CT.gov ↗
What to watch
deucravacitinib · SotyktuPhase 3
Est. primary completion 2026-10-19 · Bristol-Myers Squibb · Systemic Lupus Erythematosus
NCT05620407 · CT.gov ↗
What to watch
tralokinumab · AdbryPhase 3
Est. primary completion 2026-10-20 · AstraZeneca + LEO Pharma · Atopic Dermatitis
NCT06311682 · CT.gov ↗
What to watch
UlotarontPhase 3
Est. primary completion 2026-10-20 · Otsuka Holdings + Sumitomo Pharma · Schizophrenia
NCT06894212 · CT.gov ↗
What to watch
OcrelizumabPhase 3
Est. primary completion 2026-10-22 · Roche · Multiple Sclerosis
NCT03523858 · CT.gov ↗
What to watch
TelitaciceptPhase 3
Est. primary completion 2026-10-24 · ADARx Pharmaceuticals + RemeGen Co., Ltd. · Nephrotic Syndrome in Children, Telitacicept
NCT06125405 · CT.gov ↗
What to watch
Inclisiran · LeqvioPhase 3
Est. primary completion 2026-10-26 · Alnylam Pharmaceuticals + Novartis · Atherosclerotic Cardiovascular Disease
NCT05360446 · CT.gov ↗
What to watch
nemolizumab · NemluvioPhase 3
Est. primary completion 2026-10-26 · Chugai Pharma · Prurigo Nodularis
NCT04204616 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-10-28 · Merck & Co. · Carcinoma, Renal Cell
NCT05239728 · CT.gov ↗
What to watch
AK104Phase 3
Est. primary completion 2026-10-28 · Akeso · Non-Small Cell Lung Cancer
NCT06617416 · CT.gov ↗
What to watch
afimkibartPhase 3
Est. primary completion 2026-10-29 · Pfizer + Roche · Ulcerative Colitis
NCT06588855 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2026-10-30 · · Type 2 Diabetes
NCT07026968 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2026-10-30 · AstraZeneca · Type 2 Diabetes
NCT07026968 · CT.gov ↗
What to watch
AfuresertibPhase 3
Est. primary completion 2026-10-30 · Laekna Limited + Novartis · HR+/HER2- Metastatic Breast Cancer
NCT04851613 · CT.gov ↗
What to watch
Fulvestrant · FaslodexPhase 3
Est. primary completion 2026-10-30 · AstraZeneca · HR+/HER2- Metastatic Breast Cancer
NCT04851613 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-10-30 · Merck & Co. · Melanoma
NCT04657991 · CT.gov ↗
BinimetinibPhase 3
Est. primary completion 2026-10-30 · Pfizer · Melanoma
NCT04657991 · CT.gov ↗
EncorafenibPhase 3
Est. primary completion 2026-10-30 · Pfizer · Melanoma
NCT04657991 · CT.gov ↗
Vanzacaftor / tezacaftor / deutivacaftor · AlyftrekPhase 3
Est. primary completion 2026-10-30 · Vertex Pharmaceuticals · Cystic Fibrosis
NCT05444257 · CT.gov ↗
AND017Phase 3
Est. primary completion 2026-10-30 · Kind Pharmaceuticals · Chronic Kidney Disease
NCT07494409 · CT.gov ↗
What to watch
ANX007Phase 3
Est. primary completion 2026-10-31 · Annexon, Inc. · Age-Related Macular Degeneration
NCT06510816 · CT.gov ↗
What to watch
VonaprumentPhase 3
Est. primary completion 2026-10-31 · Annexon, Inc. · Age-Related Macular Degeneration
NCT06510816 · CT.gov ↗
What to watch
DalpiciclibPhase 3
Est. primary completion 2026-10-31 · Jiangsu Hengrui Pharmaceuticals · HR+/HER2- Metastatic Breast Cancer
NCT04842617 · CT.gov ↗
What to watch
PalazestrantPhase 3
Est. primary completion 2026-10-31 · Olema Pharmaceuticals, Inc. · HR+/HER2- Metastatic Breast Cancer
NCT06016738 · CT.gov ↗
What to watch
CapivasertibPhase 3
Est. primary completion 2026-10-31 · AstraZeneca · HR+/HER2- Metastatic Breast Cancer
NCT06635447 · CT.gov ↗
What to watch
Fulvestrant · FaslodexPhase 3
Est. primary completion 2026-10-31 · AstraZeneca · HR+/HER2- Metastatic Breast Cancer
NCT06635447 · CT.gov ↗
What to watch
BexicaserinPhase 3
Est. primary completion 2026-10-31 · H. Lundbeck · Epilepsy
NCT06719141 · CT.gov ↗
What to watch
UblituximabPhase 3
Est. primary completion 2026-10-31 · TG THERAPEUTICS, INC. · Multiple Sclerosis
NCT07211633 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-10-31 · Merck & Co. · Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma …
NCT03244384 · CT.gov ↗
What to watch
SintilimabPhase 3
Est. primary completion 2026-10-31 · Innovent Biologics · Hepatocellular Carcinoma Non-resectable
NCT05608200 · CT.gov ↗
What to watch
Olanzapine (Zyprexa) · ZyprexaPhase 3
Est. primary completion 2026-10-31 · Cheplapharm Arzneimittel GmbH + Eli Lilly · Cannabinoid Hyperemesis Syndrome
NCT07246187 · CT.gov ↗
What to watch
HaloperidolPhase 3
Est. primary completion 2026-10-31 · Johnson & Johnson · Cannabinoid Hyperemesis Syndrome
NCT07246187 · CT.gov ↗
What to watch
Dexmedetomidine · IgalmiPhase 3
Est. primary completion 2026-10-31 · BioXcel Therapeutics, Inc. · Medical Thoracoscopy
NCT07184801 · CT.gov ↗
Staccato AlprazolamPhase 3
Est. primary completion 2026-10-31 · UCB · Epilepsy
NCT05077904 · CT.gov ↗
What to watch
November 2026 (71)
tirzepatide · Zepbound / MounjaroPhase 3
Est. primary completion 2026-11 · Eli Lilly · Obesity
NCT06962280 · CT.gov ↗
What to watch
tirzepatide · Zepbound / MounjaroPhase 3
Est. primary completion 2026-11 · Eli Lilly · Obesity
NCT06914895 · CT.gov ↗
What to watch
retatrutidePhase 3
Est. primary completion 2026-11 · Eli Lilly · Obesity
NCT06662383 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-11 · Merck & Co. · Non-Small Cell Lung Cancer
NCT06448312 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3
Est. primary completion 2026-11 · Merck & Co. · Non-Small Cell Lung Cancer
NCT06448312 · CT.gov ↗
What to watch
ObicetrapibPhase 3
Est. primary completion 2026-11 · NewAmsterdam Pharma · Atherosclerotic Cardiovascular Disease
NCT05202509 · CT.gov ↗
What to watch
OcrelizumabPhase 3
Est. primary completion 2026-11 · Roche · Multiple Sclerosis
NCT06847724 · CT.gov ↗
What to watch
BL-B01D1Phase 3
Est. primary completion 2026-11 · Sichuan Baili Pharmaceutical · Nasopharyngeal Carcinoma
NCT06118333 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-11 · Eli Lilly · Nasopharyngeal Carcinoma
NCT06118333 · CT.gov ↗
What to watch
DocetaxelPhase 3
Est. primary completion 2026-11 · Sanofi · Nasopharyngeal Carcinoma
NCT06118333 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2026-11 · Cheplapharm Arzneimittel GmbH · Nasopharyngeal Carcinoma
NCT06118333 · CT.gov ↗
What to watch
Cenobamate · XcopriPhase 3
Est. primary completion 2026-11 · SK Biopharmaceuticals Co., Ltd. · Epilepsy
NCT05067634 · CT.gov ↗
What to watch
vidofludimus calciumPhase 3
Est. primary completion 2026-11 · Immunic, Inc. · Multiple Sclerosis
NCT05201638 · CT.gov ↗
vidofludimus calciumPhase 3
Est. primary completion 2026-11 · Immunic, Inc. · Multiple Sclerosis
NCT05134441 · CT.gov ↗
TislelizumabPhase 3
Est. primary completion 2026-11 · BeOne Medicines · Advanced and Metastatic NSCLC
NCT06704620 · CT.gov ↗
pemetrexed · AlimtaPhase 3
Est. primary completion 2026-11 · Eli Lilly · Non-Small Cell Lung Cancer
NCT06704620 · CT.gov ↗
What to watch
Abatacept · OrenciaPhase 3
Est. primary completion 2026-11 · Bristol-Myers Squibb · Rheumatoid Arthritis
NCT05428488 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2026-11 · · Steinert's Disease, Myotonic Dystrophy 1, Metformin
NCT05532813 · CT.gov ↗
What to watch
Tadalafil · AdcircaPhase 3
Est. primary completion 2026-11 · Eli Lilly · Fontan Palliation
NCT05206955 · CT.gov ↗
What to watch
LNK01001Phase 3
Est. primary completion 2026-11 · Lynk Pharmaceuticals · Ankylosing Spondylitis
NCT07237568 · CT.gov ↗
What to watch
AK104Phase 3
Est. primary completion 2026-11 · Akeso · Gastric and Gastroesophageal Junction Adenocarcinoma
NCT06341335 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2026-11 · · Moderate to Severe Atopic Dermatitis
NCT06239311 · CT.gov ↗
What to watch
TemozolomidePhase 3
Est. primary completion 2026-11 · Merck & Co. · High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
NCT04221035 · CT.gov ↗
What to watch
DinutuximabPhase 3
Est. primary completion 2026-11 · United Therapeutics · Neuroblastoma
NCT04221035 · CT.gov ↗
apitegromabPhase 3
Est. primary completion 2026-11-01 · Scholar Rock · Spinal Muscular Atrophy
NCT05626855 · CT.gov ↗
What to watch
Olanzapine (Zyprexa) · ZyprexaPhase 3
Est. primary completion 2026-11-01 · Cheplapharm Arzneimittel GmbH + Eli Lilly · Misuse, Opioid
NCT06200181 · CT.gov ↗
What to watch
Dexmedetomidine · IgalmiPhase 3
Est. primary completion 2026-11-01 · BioXcel Therapeutics, Inc. · Cough Suppression
NCT07213037 · CT.gov ↗
DocetaxelPhase 3
Est. primary completion 2026-11-01 · Sanofi · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
NCT04447352 · CT.gov ↗
What to watch
Clemizole (EPX-100)Phase 3
Est. primary completion 2026-11-01 · Harmony Biosciences · Lennox Gastaut Syndrome
NCT05066217 · CT.gov ↗
What to watch
cyclosporinePhase 3
Est. primary completion 2026-11-01 · Harrow, Inc. · Primary Autoimmune Hemolytic Anemia
NCT05057468 · CT.gov ↗
Xanomeline/trospium chloride · CobenfyPhase 3
Est. primary completion 2026-11-01 · Bristol-Myers Squibb · Bipolar-I Disorder With Mania or Mania With Mixed Features
NCT06951698 · CT.gov ↗
What to watch
EnvafolimabPhase 3
Est. primary completion 2026-11-01 · Ascletis Pharma + Suzhou Alphamab · Rectal Cancer
NCT05752136 · CT.gov ↗
baricitinib · OlumiantPhase 3
Est. primary completion 2026-11-01 · Eli Lilly · Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
NCT06631287 · CT.gov ↗
What to watch
AnifrolumabPhase 3
Est. primary completion 2026-11-02 · AstraZeneca + MedImmune LLC · Cutaneous Lupus Erythematosus
NCT06015737 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3
Est. primary completion 2026-11-02 · Bristol-Myers Squibb · Bipolar Disorder Type I With Mania or Mania With Mixed Features
NCT06951711 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2026-11-04 · AstraZeneca · Type 2 Diabetes, Atherosclerotic Cardiovascular Disease
NCT06772168 · CT.gov ↗
What to watch
RosuvastatinPhase 3
Est. primary completion 2026-11-04 · AstraZeneca · Atherosclerotic Cardiovascular Disease
NCT06772168 · CT.gov ↗
What to watch
itepekimabPhase 3
Est. primary completion 2026-11-06 · Regeneron Pharmaceuticals + Sanofi · Chronic Rhinosinusitis With Nasal Polyps
NCT06834360 · CT.gov ↗
What to watch
DaratumumabPhase 3
Est. primary completion 2026-11-08 · Johnson & Johnson · Anti-N-Methyl-D-Aspartate Receptor Encephalitis
NCT06867991 · CT.gov ↗
What to watch
OfatumumabPhase 3
Est. primary completion 2026-11-08 · Novartis · Anti-N-Methyl-D-Aspartate Receptor Encephalitis
NCT06867991 · CT.gov ↗
What to watch
Roxadustat · EvrenzoPhase 3
Est. primary completion 2026-11-10 · Astellas Pharma + AstraZeneca + Kyntra Bio · Perioperative Anemia
NCT06772272 · CT.gov ↗
What to watch
RosuvastatinPhase 3
Est. primary completion 2026-11-10 · AstraZeneca · Cardiovascular
NCT07239414 · CT.gov ↗
What to watch
Bempedoic acid · NexletolPhase 3
Est. primary completion 2026-11-10 · Esperion Therapeutics · Cardiovascular
NCT07239414 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3
Est. primary completion 2026-11-11 · AstraZeneca + Daiichi Sankyo · Breast Cancer; HER2-positive; Metastatic
NCT04784715 · CT.gov ↗
What to watch
GoserelinPhase 3
Est. primary completion 2026-11-11 · AstraZeneca + TerSera Therapeutics LLC · Prostate Adenocarcinoma
NCT05050084 · CT.gov ↗
What to watch
InavolisibPhase 3
Est. primary completion 2026-11-13 · Roche · HR+/HER2- Metastatic Breast Cancer
NCT05646862 · CT.gov ↗
What to watch
Fulvestrant · FaslodexPhase 3
Est. primary completion 2026-11-13 · AstraZeneca · HR+/HER2- Metastatic Breast Cancer
NCT05646862 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2026-11-14 · Roche · Primary Immune Thrombocytopenia (ITP)
NCT05338190 · CT.gov ↗
What to watch
deucravacitinib · SotyktuPhase 3
Est. primary completion 2026-11-18 · Bristol-Myers Squibb · Sjögren's Syndrome
NCT05946941 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-11-20 · Merck & Co. · Endometrial Neoplasms
NCT04634877 · CT.gov ↗
What to watch
DocetaxelPhase 3
Est. primary completion 2026-11-20 · Sanofi · Endometrial Neoplasms
NCT04634877 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2026-11-20 · · Osteo Arthritis Knee
NCT06231758 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3
Est. primary completion 2026-11-24 · Bristol-Myers Squibb · Alzheimer's Disease
NCT06585787 · CT.gov ↗
What to watch
ICP-332Phase 3
Est. primary completion 2026-11-25 · Beijing InnoCare Pharma Tech Co. · Atopic Dermatitis
NCT06775860 · CT.gov ↗
What to watch
NiraparibPhase 3
Est. primary completion 2026-11-26 · GlaxoSmithKline + Zai Lab · Neoplasms
NCT03981796 · CT.gov ↗
What to watch
DostarlimabPhase 3
Est. primary completion 2026-11-26 · GlaxoSmithKline · Neoplasms
NCT03981796 · CT.gov ↗
What to watch
MT1013Phase 3
Est. primary completion 2026-11-26 · Shaanxi Micot Pharmaceutical Technology · Chronic Kidney Disease
NCT07122401 · CT.gov ↗
What to watch
Rimegepant (Nurtec ODT) · Nurtec ODTPhase 3
Est. primary completion 2026-11-29 · Pfizer · Migraine
NCT06641466 · CT.gov ↗
rilzabrutinibPhase 3
Est. primary completion 2026-11-30 · Sanofi · Immune Thrombocytopenia
NCT07216079 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2026-11-30 · · Acute Lymphoblastic Leukemia, Pediatric
NCT03020030 · CT.gov ↗
What to watch
tamoxifenPhase 3
Est. primary completion 2026-11-30 · Mayne Pharma · HR+/HER2- Metastatic Breast Cancer
NCT04906395 · CT.gov ↗
AnastrozolePhase 3
Est. primary completion 2026-11-30 · ANI Pharmaceuticals, Inc. + AstraZeneca · HR+/HER2- Metastatic Breast Cancer
NCT04906395 · CT.gov ↗
LetrozolePhase 3
Est. primary completion 2026-11-30 · Novartis · HR+/HER2- Metastatic Breast Cancer
NCT04906395 · CT.gov ↗
ExemestanePhase 3
Est. primary completion 2026-11-30 · Pfizer · HR+/HER2- Metastatic Breast Cancer
NCT04906395 · CT.gov ↗
Doravirine · PifeltroPhase 3
Est. primary completion 2026-11-30 · Merck & Co. · HIV
NCT04892654 · CT.gov ↗
What to watch
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)Phase 3
Est. primary completion 2026-11-30 · ViiV Healthcare · HIV
NCT04892654 · CT.gov ↗
What to watch
WD-890Phase 3
Est. primary completion 2026-11-30 · Ningbo/Zhejiang Wenda Pharma Technology Co. · Psoriasis
NCT07672561 · CT.gov ↗
What to watch
Furosemide (subcutaneous, scPharmaceuticals) · FUROSCIXPhase 3
Est. primary completion 2026-11-30 · MannKind Corporation + scPharmaceuticals · Heart Failure
NCT07008365 · CT.gov ↗
What to watch
Furosemide (subcutaneous, SQ Innovation) · Lasix ONYUPhase 3
Est. primary completion 2026-11-30 · SQ Innovation · Heart Failure
NCT07008365 · CT.gov ↗
What to watch
Ferric carboxymaltose · Injectafer / FerinjectPhase 3
Est. primary completion 2026-11-30 · Vifor Pharma · Advanced Gastric Carcinoma
NCT05226169 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-11-30 · Eli Lilly · Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy
NCT06156514 · CT.gov ↗
What to watch
December 2026 (190)
Resmetirom · RezdiffraPhase 3
Est. primary completion 2026-12 · Madrigal Pharmaceuticals · MASH / NASH
NCT05500222 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-12 · Merck & Co. · Non-Small Cell Lung Cancer
NCT06711900 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3
Est. primary completion 2026-12 · Merck & Co. · Non-Small Cell Lung Cancer
NCT06711900 · CT.gov ↗
What to watch
BL-B01D1Phase 3
Est. primary completion 2026-12 · Sichuan Baili Pharmaceutical · Non-Small Cell Lung Cancer
NCT06382129 · CT.gov ↗
What to watch
DocetaxelPhase 3
Est. primary completion 2026-12 · Sanofi · Non-small Cell Lung Cancer
NCT06382129 · CT.gov ↗
What to watch
SHR-A2009Phase 3
Est. primary completion 2026-12 · Jiangsu Hengrui Pharmaceuticals · Non-Small Cell Lung Cancer
NCT06671379 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3
Est. primary completion 2026-12 · Gilead Sciences · HR+/HER2- Metastatic Breast Cancer
NCT04639986 · CT.gov ↗
What to watch
tamoxifenPhase 3
Est. primary completion 2026-12 · Mayne Pharma · HR+/HER2- Metastatic Breast Cancer
NCT05780567 · CT.gov ↗
What to watch
AnastrozolePhase 3
Est. primary completion 2026-12 · ANI Pharmaceuticals, Inc. + AstraZeneca · HR+/HER2- Metastatic Breast Cancer
NCT05780567 · CT.gov ↗
What to watch
LetrozolePhase 3
Est. primary completion 2026-12 · Novartis · HR+/HER2- Metastatic Breast Cancer
NCT05780567 · CT.gov ↗
What to watch
CulmerciclibPhase 3
Est. primary completion 2026-12 · Sino Biopharmaceutical · HR+/HER2- Metastatic Breast Cancer
NCT05780567 · CT.gov ↗
What to watch
VormatriginePhase 3
Est. primary completion 2026-12 · Praxis Precision Medicines, Inc. · Epilepsy
NCT07010471 · CT.gov ↗
What to watch
RelutriginePhase 3
Est. primary completion 2026-12 · Praxis Precision Medicines, Inc. · Epilepsy
NCT07010471 · CT.gov ↗
What to watch
DurvalumabPhase 3
Est. primary completion 2026-12 · AstraZeneca · Oropharyngeal Cancer
NCT04116047 · CT.gov ↗
What to watch
PenpulimabPhase 3
Est. primary completion 2026-12 · Akeso · Advanced Hepatocellular Carcinoma (HCC)
NCT04344158 · CT.gov ↗
What to watch
BL-B01D1Phase 3
Est. primary completion 2026-12 · Sichuan Baili Pharmaceutical · Small Cell Lung Cancer
NCT06500026 · CT.gov ↗
What to watch
TinengotinibPhase 3
Est. primary completion 2026-12 · TransThera Sciences (Nanjing), Inc. · Cholangiocarcinoma
NCT05948475 · CT.gov ↗
What to watch
Budesonide · PulmicortPhase 3
Est. primary completion 2026-12 · AstraZeneca · Eosinophilic Esophagitis
NCT06596252 · CT.gov ↗
What to watch
lutikizumabPhase 3
Est. primary completion 2026-12 · AbbVie · Hidradenitis Suppurativa
NCT06468228 · CT.gov ↗
What to watch
Palbociclib · IbrancePhase 3
Est. primary completion 2026-12 · Pfizer · HR+/HER2- Metastatic Breast Cancer
NCT03820830 · CT.gov ↗
NivolumabPhase 3
Est. primary completion 2026-12 · Bristol-Myers Squibb · Metastatic Colon Cancer, Stage III Colon Cancer
NCT03803553 · CT.gov ↗
What to watch
BinimetinibPhase 3
Est. primary completion 2026-12 · Pfizer · Metastatic Colon Cancer, Stage III Colon Cancer
NCT03803553 · CT.gov ↗
What to watch
EncorafenibPhase 3
Est. primary completion 2026-12 · Pfizer · Metastatic Colon Cancer, Stage III Colon Cancer
NCT03803553 · CT.gov ↗
What to watch
MasupirdinePhase 3
Est. primary completion 2026-12 · Suven Life Sciences · Agitation, Alzheimer's Type Dementia
NCT05397639 · CT.gov ↗
What to watch
Donidalorsen · DawnzeraPhase 3
Est. primary completion 2026-12 · Ionis Pharmaceuticals · Hereditary Angioedema
NCT05392114 · CT.gov ↗
RalinepagPhase 3
Est. primary completion 2026-12 · United Therapeutics · Hypertension, Pulmonary Arterial Hypertension
NCT03683186 · CT.gov ↗
What to watch
tirzepatide · Zepbound / MounjaroPhase 3
Est. primary completion 2026-12 · Eli Lilly · Obesity
NCT07298915 · CT.gov ↗
What to watch
difamilast · Moizerto / AdqueyPhase 3
Est. primary completion 2026-12 · Acrotech Biopharma + Otsuka Holdings · Atopic Dermatitis
NCT07173478 · CT.gov ↗
What to watch
ribupatidePhase 3
Est. primary completion 2026-12 · Jiangsu Hengrui Pharmaceuticals + Kailera Therapeutics · Obesity
NCT06994650 · CT.gov ↗
What to watch
ribupatidePhase 3
Est. primary completion 2026-12 · Jiangsu Hengrui Pharmaceuticals + Kailera Therapeutics · Obesity
NCT06974851 · CT.gov ↗
What to watch
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)Phase 3
Est. primary completion 2026-12 · ViiV Healthcare · HIV
NCT06747507 · CT.gov ↗
What to watch
Fampridine · Ampyra / FampyraPhase 3
Est. primary completion 2026-12 · Merz Therapeutics · Multiple Sclerosis
NCT06136728 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12 · Roche · Non-Small Cell Lung Cancer
NCT05654454 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2026-12 · · Type 2 Diabetes
NCT07093476 · CT.gov ↗
What to watch
Alogliptin · NesinaPhase 3
Est. primary completion 2026-12 · Takeda Pharmaceutical Company · Type 2 Diabetes
NCT07093476 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2026-12 · Boehringer Ingelheim + Eli Lilly · Type 2 Diabetes
NCT07093476 · CT.gov ↗
What to watch
Nab-paclitaxelPhase 3
Est. primary completion 2026-12 · Bristol-Myers Squibb · Triple-Negative Breast Cancer (TNBC)
NCT06767527 · CT.gov ↗
What to watch
IvonescimabPhase 3
Est. primary completion 2026-12 · Akeso + Summit Therapeutics · Triple-Negative Breast Cancer (TNBC)
NCT06767527 · CT.gov ↗
What to watch
Lumateperone · CaplytaPhase 3
Est. primary completion 2026-12 · Intra-Cellular Therapies + Johnson & Johnson · Schizophrenia
NCT06482554 · CT.gov ↗
What to watch
Risperidone (Risperdal) · RisperdalPhase 3
Est. primary completion 2026-12 · Johnson & Johnson · Schizophrenia
NCT06482554 · CT.gov ↗
What to watch
ElsunersenPhase 3
Est. primary completion 2026-12 · Praxis Precision Medicines, Inc. · Epilepsy
NCT07019922 · CT.gov ↗
What to watch
SeralutinibPhase 3
Est. primary completion 2026-12 · Gossamer Bio · Pulmonary Arterial Hypertension
NCT06274801 · CT.gov ↗
What to watch
pemetrexed · AlimtaPhase 3
Est. primary completion 2026-12 · Eli Lilly · Non-Small Cell Lung Cancer
NCT06754644 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3
Est. primary completion 2026-12 · AbbVie · Long COVID
NCT06928272 · CT.gov ↗
What to watch
Pirfenidone (Esbriet) · EsbrietPhase 3
Est. primary completion 2026-12 · Genentech (Roche Group) + Roche · Long COVID
NCT06928272 · CT.gov ↗
apremilast · OtezlaPhase 3
Est. primary completion 2026-12 · Amgen · Recurrent Aphtous Stomatitis
NCT04227314 · CT.gov ↗
What to watch
Sacubitril/valsartan · EntrestoPhase 3
Est. primary completion 2026-12 · Novartis · Congenital Heart Disease
NCT06693674 · CT.gov ↗
What to watch
Solriamfetol · SunosiPhase 3
Est. primary completion 2026-12 · Axsome Therapeutics · Binge-Eating Disorder
NCT06413433 · CT.gov ↗
What to watch
Solriamfetol · SunosiPhase 3
Est. primary completion 2026-12 · Axsome Therapeutics · Excessive Sleepiness, Shift-work Disorder
NCT06568367 · CT.gov ↗
What to watch
SintilimabPhase 3
Est. primary completion 2026-12 · Innovent Biologics · Gastric Cancer
NCT05918094 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-12 · BeOne Medicines · Nasopharyngeal Carcinoma
NCT06177301 · CT.gov ↗
ToripalimabPhase 3
Est. primary completion 2026-12 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Nasopharyngeal Carcinoma
NCT05340491 · CT.gov ↗
What to watch
NiraparibPhase 3
Est. primary completion 2026-12 · GlaxoSmithKline + Zai Lab · Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
NCT03903835 · CT.gov ↗
What to watch
CapivasertibPhase 3
Est. primary completion 2026-12 · AstraZeneca · Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
NCT03903835 · CT.gov ↗
What to watch
DocetaxelPhase 3
Est. primary completion 2026-12 · Sanofi · Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
NCT03903835 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2026-12 · · Cardiac Sarcoidosis, Sarcoidosis
NCT03593759 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12 · Eli Lilly · Pancreatic Ductal Adenocarcinoma
NCT04969731 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12 · Eli Lilly · Bladder Cancer, Bladder Urothelial Carcinoma
NCT04574960 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2026-12 · Cheplapharm Arzneimittel GmbH · Cancer of Rectum
NCT04095299 · CT.gov ↗
What to watch
RYZ101Phase 3
Est. primary completion 2026-12 · Bristol-Myers Squibb · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors …
NCT05477576 · CT.gov ↗
What to watch
Nab-paclitaxelPhase 3
Est. primary completion 2026-12 · Bristol-Myers Squibb · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer …
NCT05281471 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12 · Roche · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer …
NCT05281471 · CT.gov ↗
What to watch
Olvimulogene nanivacirepvecPhase 3
Est. primary completion 2026-12 · Genelux Corporation · Ovarian Cancer
NCT05281471 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12 · Eli Lilly · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer …
NCT05281471 · CT.gov ↗
What to watch
DocetaxelPhase 3
Est. primary completion 2026-12 · Sanofi · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer …
NCT05281471 · CT.gov ↗
What to watch
stapokibartPhase 3
Est. primary completion 2026-12 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. + Keymed Biosciences · Seasonal Allergic Rhinitis (SAR)
NCT07678931 · CT.gov ↗
What to watch
semaglutide · Wegovy / Ozempic / RybelsusPhase 3
Est. primary completion 2026-12 · Novo Nordisk · Type 2 Diabetes
NCT07059377 · CT.gov ↗
AtezolizumabPhase 3
Est. primary completion 2026-12 · Roche · Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma …
NCT05482516 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12 · Roche · Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma …
NCT05482516 · CT.gov ↗
What to watch
DurvalumabPhase 3
Est. primary completion 2026-12 · AstraZeneca · Non-Small Cell Lung Cancer
NCT04585490 · CT.gov ↗
TremelimumabPhase 3
Est. primary completion 2026-12 · MedImmune LLC · Non-Small Cell Lung Cancer
NCT04585490 · CT.gov ↗
pemetrexed · AlimtaPhase 3
Est. primary completion 2026-12 · Eli Lilly · Non-Small Cell Lung Cancer
NCT04585490 · CT.gov ↗
RAY1225Phase 3
Est. primary completion 2026-12-01 · Guangdong Raynovent Biotech · T2DM
NCT07139548 · CT.gov ↗
What to watch
RAY1225Phase 3
Est. primary completion 2026-12-01 · Guangdong Raynovent Biotech · T2DM
NCT07139535 · CT.gov ↗
What to watch
AND017Phase 3
Est. primary completion 2026-12-01 · Kind Pharmaceuticals · Chronic Kidney Disease
NCT07487727 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2026-12-01 · Roche · Acute Myeloid Leukemia
NCT07712848 · CT.gov ↗
tradipitantPhase 3
Est. primary completion 2026-12-01 · Vanda Pharmaceuticals · Nausea and Vomiting, Obesity
NCT07446439 · CT.gov ↗
PembrolizumabPhase 3
Est. primary completion 2026-12-01 · Merck & Co. · Head and Neck Neoplasms
NCT06998069 · CT.gov ↗
What to watch
Trastuzumab DeruxtecanPhase 3
Est. primary completion 2026-12-06 · AstraZeneca + Daiichi Sankyo · Nausea and Vomiting Caused by Trastuzumab Deruxtecan
NCT07716189 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12-06 · Eli Lilly · Nausea and Vomiting Caused by Chemotherapy
NCT07716228 · CT.gov ↗
What to watch
DocetaxelPhase 3
Est. primary completion 2026-12-06 · Sanofi · Nausea and Vomiting Caused by Chemotherapy
NCT07716176 · CT.gov ↗
What to watch
Eculizumab · SolirisPhase 3
Est. primary completion 2026-12-07 · Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) · NMOSD, Neuromyelitis Optica Spectrum Disorders
NCT06724809 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3
Est. primary completion 2026-12-09 · Bristol-Myers Squibb · Alzheimer's Disease
NCT06126224 · CT.gov ↗
What to watch
ZongertinibPhase 3
Est. primary completion 2026-12-10 · Boehringer Ingelheim · Lung Cancer, Non-squamous, Non-small Cell
NCT06151574 · CT.gov ↗
What to watch
GZR18Phase 3
Est. primary completion 2026-12-11 · Gan & Lee Pharmaceuticals · Type 2 Diabetes Mellitus (T2DM)
NCT06778967 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 3
Est. primary completion 2026-12-12 · AstraZeneca · Non-Small Cell Lung Cancer
NCT07376382 · CT.gov ↗
CPO301Phase 3
Est. primary completion 2026-12-12 · Conjupro Biotherapeutics, Inc. · Non-Small Cell Lung Cancer
NCT07376382 · CT.gov ↗
What to watch
Abp 234Phase 3
Est. primary completion 2026-12-14 · Amgen · Non-Small Cell Lung Cancer
NCT06430866 · CT.gov ↗
What to watch
AtezolizumabPhase 3
Est. primary completion 2026-12-15 · Roche · Invasive Breast Cancer
NCT03595592 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2026-12-15 · Bristol-Myers Squibb · Non-Clear Cell Renal Cell Carcinoma
NCT05678673 · CT.gov ↗
What to watch
ZanzalintinibPhase 3
Est. primary completion 2026-12-15 · Exelixis · Clear Cell Renal Cell Carcinoma
NCT05678673 · CT.gov ↗
What to watch
Cariprazine (Vraylar) · VraylarPhase 3
Est. primary completion 2026-12-15 · AbbVie + Gedeon Richter + Tanabe Pharma Corporation · Schizophrenia
NCT03817502 · CT.gov ↗
What to watch
N-acetylcysteinePhase 3
Est. primary completion 2026-12-15 · Cumberland Pharmaceuticals Inc. · Psychosis
NCT05796401 · CT.gov ↗
TemozolomidePhase 3
Est. primary completion 2026-12-15 · Merck & Co. · Neuroblastoma (NB), Ganglioneuroblastoma
NCT07375563 · CT.gov ↗
What to watch
DinutuximabPhase 3
Est. primary completion 2026-12-15 · United Therapeutics · Neuroblastoma
NCT07375563 · CT.gov ↗
HB1801Phase 3
Est. primary completion 2026-12-16 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Early or Locally Advanced HER2-positive Breast Cancer
NCT06747338 · CT.gov ↗
What to watch
Elafibranor · IqirvoPhase 3
Est. primary completion 2026-12-17 · Genfit · Primary Biliary Cholangitis
NCT06730061 · CT.gov ↗
bimekizumab · BimzelxPhase 3
Est. primary completion 2026-12-21 · UCB · Hidradenitis Suppurativa
NCT06921850 · CT.gov ↗
What to watch
Aflibercept · EyleaPhase 3
Est. primary completion 2026-12-22 · Amgen + Biocon + Celltrion + Formycon AG + Harrow, Inc. + Regeneron Pharmaceuticals + Sandoz Group AG · Age-Related Macular Degeneration
NCT06856577 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-12-22 · Merck & Co. · Non-Small Cell Lung Cancer
NCT03774732 · CT.gov ↗
What to watch
SuzetriginePhase 3
Est. primary completion 2026-12-22 · Vertex Pharmaceuticals · Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative Pain
NCT07539623 · CT.gov ↗
What to watch
Benralizumab · FasenraPhase 3
Est. primary completion 2026-12-23 · AstraZeneca + MedImmune LLC · Asthma
NCT05692180 · CT.gov ↗
What to watch
VemurafenibPhase 3
Est. primary completion 2026-12-24 · Roche · Colorectal Cancer Metastatic
NCT06008119 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12-25 · Eli Lilly · Locally Advanced Pancreatic Cancer
NCT05653453 · CT.gov ↗
What to watch
Trelagliptin · ZafatekPhase 3
Est. primary completion 2026-12-26 · Takeda Pharmaceutical Company · Type 2 Diabetes
NCT07073768 · CT.gov ↗
What to watch
CarfilzomibPhase 3
Est. primary completion 2026-12-28 · Amgen + Johnson & Johnson · Multiple Myeloma
NCT03729804 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2026-12-28 · Takeda Pharmaceutical Company · Multiple Myeloma
NCT03729804 · CT.gov ↗
What to watch
LenalidomidePhase 3
Est. primary completion 2026-12-28 · Bristol-Myers Squibb + Celgene Corporation · Multiple Myeloma
NCT03729804 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-28 · OCULAR THERAPEUTIX, INC · Multiple Myeloma
NCT03729804 · CT.gov ↗
TH-SC01Phase 3
Est. primary completion 2026-12-28 · Jiangsu Topcel-KH Pharmaceutical · Crohn's Disease
NCT06925594 · CT.gov ↗
What to watch
Olanzapine (Zyprexa) · ZyprexaPhase 3
Est. primary completion 2026-12-28 · Cheplapharm Arzneimittel GmbH + Eli Lilly · Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology
NCT07633236 · CT.gov ↗
What to watch
Palbociclib · IbrancePhase 3
Est. primary completion 2026-12-30 · Pfizer · HR+/HER2- Metastatic Breast Cancer
NCT05909397 · CT.gov ↗
What to watch
VepdegestrantPhase 3
Est. primary completion 2026-12-30 · Arvinas Inc. + Pfizer + Rigel Pharmaceuticals · HR+/HER2- Metastatic Breast Cancer
NCT05909397 · CT.gov ↗
What to watch
SintilimabPhase 3
Est. primary completion 2026-12-30 · Innovent Biologics · Colorectal Cancer Stage IV
NCT05171660 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12-30 · Roche · Colorectal Cancer Stage IV
NCT05171660 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2026-12-30 · Cheplapharm Arzneimittel GmbH · Colorectal Cancer Stage IV
NCT05171660 · CT.gov ↗
What to watch
Descartes-08Phase 3
Est. primary completion 2026-12-30 · Cartesian Therapeutics, Inc. · Myasthaenia Gravis
NCT06799247 · CT.gov ↗
TislelizumabPhase 3
Est. primary completion 2026-12-30 · BeOne Medicines · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
NCT06206733 · CT.gov ↗
CapecitabinePhase 3
Est. primary completion 2026-12-30 · Cheplapharm Arzneimittel GmbH · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
NCT06206733 · CT.gov ↗
What to watch
CetrelimabPhase 3
Est. primary completion 2026-12-30 · Johnson & Johnson · Urinary Bladder Neoplasms
NCT04658862 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2026-12-30 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Non-Small Cell Lung Cancer
NCT04772287 · CT.gov ↗
What to watch
JSKN003Phase 3
Est. primary completion 2026-12-30 · Alphamab Oncology + CSPC Pharmaceutical Group · Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers
NCT06751485 · CT.gov ↗
What to watch
Sodium zirconium cyclosilicate · LokelmaPhase 3
Est. primary completion 2026-12-30 · AstraZeneca · Heart Failure, Chronic Kidney Disease
NCT06578078 · CT.gov ↗
What to watch
VicagrelPhase 3
Est. primary completion 2026-12-30 · Jiangsu Vcare Pharmaceutical Technology Co., Ltd. · Atherosclerotic Cardiovascular Disease
NCT06577519 · CT.gov ↗
What to watch
Ferric derisomaltose · Monoferric / MonoferPhase 3
Est. primary completion 2026-12-30 · Pharmacosmos · Gynecologic Cancer, Anemia, Iron-deficiency
NCT05407987 · CT.gov ↗
What to watch
SeltorexantPhase 3
Est. primary completion 2026-12-30 · Johnson & Johnson · Major Depressive Disorder
NCT06559306 · CT.gov ↗
What to watch
Migalastat · GalafoldPhase 3
Est. primary completion 2026-12-31 · Amicus Therapeutics + BioMarin Pharmaceutical · Fabry Disease
NCT04020055 · CT.gov ↗
What to watch
CarfilzomibPhase 3
Est. primary completion 2026-12-31 · Amgen + Johnson & Johnson · Plasma Cell Myeloma
NCT01863550 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2026-12-31 · Takeda Pharmaceutical Company · Plasma Cell Myeloma
NCT01863550 · CT.gov ↗
What to watch
LenalidomidePhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb + Celgene Corporation · Plasma Cell Myeloma
NCT01863550 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-31 · OCULAR THERAPEUTIX, INC · Plasma Cell Myeloma
NCT01863550 · CT.gov ↗
mazdutidePhase 3
Est. primary completion 2026-12-31 · Eli Lilly + Innovent Biologics · Obesity
NCT06884293 · CT.gov ↗
What to watch
LorlatinibPhase 3
Est. primary completion 2026-12-31 · Pfizer · Non-Small Cell Lung Cancer
NCT05059522 · CT.gov ↗
What to watch
TalazoparibPhase 3
Est. primary completion 2026-12-31 · Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
NCT05059522 · CT.gov ↗
What to watch
pemetrexed · AlimtaPhase 3
Est. primary completion 2026-12-31 · Eli Lilly · Non-Small Cell Lung Cancer
NCT05059522 · CT.gov ↗
What to watch
AlmonertinibPhase 3
Est. primary completion 2026-12-31 · Hansoh Pharmaceutical Group · Lung Cancer
NCT04841811 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 3
Est. primary completion 2026-12-31 · Jiangsu Hengrui Pharmaceuticals · HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
NCT05424835 · CT.gov ↗
What to watch
AtezolizumabPhase 3
Est. primary completion 2026-12-31 · Roche · Cancer
NCT03148418 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12-31 · Roche · Cancer
NCT03148418 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-12-31 · Merck & Co. · Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 …
NCT03712605 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-12-31 · BeOne Medicines · Gastric Cancer Stage III
NCT06939439 · CT.gov ↗
ToripalimabPhase 3
Est. primary completion 2026-12-31 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Advanced Hepatocellular Carcinoma (HCC)
NCT04523493 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12-31 · Eli Lilly · Hepatoblastoma, Carcinoma, Hepatocellular
NCT03017326 · CT.gov ↗
What to watch
TemozolomidePhase 3
Est. primary completion 2026-12-31 · Merck & Co. · Brain and Central Nervous System Tumors, Neurotoxicity
NCT00978458 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-12-31 · BeOne Medicines · B-cell Malignancies
NCT04170283 · CT.gov ↗
zanubrutinib · BrukinsaPhase 3
Est. primary completion 2026-12-31 · BeOne Medicines · B-cell Malignancies
NCT04170283 · CT.gov ↗
BexicaserinPhase 3
Est. primary completion 2026-12-31 · H. Lundbeck · Epilepsy
NCT06660394 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2026-12-31 · Boehringer Ingelheim + Eli Lilly · Chronic Kidney Disease
NCT06531824 · CT.gov ↗
What to watch
VicadrostatPhase 3
Est. primary completion 2026-12-31 · Boehringer Ingelheim · Chronic Kidney Disease
NCT06531824 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb · Primary Mediastinal Large B-Cell Lymphoma
NCT04759586 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2026-12-31 · Roche · Primary Mediastinal Large B-Cell Lymphoma
NCT04759586 · CT.gov ↗
What to watch
DurvalumabPhase 3
Est. primary completion 2026-12-31 · AstraZeneca · Cancer
NCT05303532 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3
Est. primary completion 2026-12-31 · AbbVie · Crohn's Disease
NCT07149467 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2026-12-31 · Roche · Acute Myeloid Leukemia
NCT07486479 · CT.gov ↗
AzacitidinePhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb · Acute Myeloid Leukemia
NCT07486479 · CT.gov ↗
What to watch
ChidamidePhase 3
Est. primary completion 2026-12-31 · Chipscreen Biosciences · Extranodal Natural Killer T Cell Lymphoma
NCT06255795 · CT.gov ↗
What to watch
SuzetriginePhase 3
Est. primary completion 2026-12-31 · Vertex Pharmaceuticals · Opioid Consumption, Postoperative, Multimodal Analgesia, Ureteroscopy, Ureteral Stents, Ureteral Stent-Related Symptoms
NCT07654296 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2026-12-31 · Boehringer Ingelheim + Eli Lilly · Heart Failure
NCT05392764 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2026-12-31 · Roche · Acute Myeloid Leukemia
NCT06990321 · CT.gov ↗
AzacitidinePhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb · Acute Myeloid Leukemia
NCT06345365 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2026-12-31 · AstraZeneca · Heart Failure
NCT06304857 · CT.gov ↗
What to watch
CamrelizumabPhase 3
Est. primary completion 2026-12-31 · Jiangsu Hengrui Pharmaceuticals · Triple-negative Breast Cancer
NCT06533384 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2026-12-31 · Cheplapharm Arzneimittel GmbH · Triple-negative Breast Cancer
NCT06533384 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3
Est. primary completion 2026-12-31 · Merck & Co. · HR+/HER2- Metastatic Breast Cancer
NCT06081959 · CT.gov ↗
What to watch
SC0062Phase 3
Est. primary completion 2026-12-31 · BioCity Biopharmaceutics · Chronic Kidney Disease
NCT06819826 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2026-12-31 · AstraZeneca · Pediatric Hereditary Kidney Diseases
NCT06890143 · CT.gov ↗
What to watch
Ferric derisomaltose · Monoferric / MonoferPhase 3
Est. primary completion 2026-12-31 · Pharmacosmos · Iron Deficiency Anaemia in Childbirth
NCT05251493 · CT.gov ↗
What to watch
Eculizumab · SolirisPhase 3
Est. primary completion 2026-12-31 · Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) · Neuromyelitis Optica Spectrum Disorders (NMOSD)
NCT07420296 · CT.gov ↗
What to watch
Azvudine · FNCPhase 3
Est. primary completion 2026-12-31 · Henan Genuine Biotech · Chronic Hepatitis B, Azvudine
NCT07307586 · CT.gov ↗
What to watch
Icosapent Ethyl · VascepaPhase 3
Est. primary completion 2026-12-31 · Amarin Corporation · Inflammation, Community Acquired Pneumonia (CAP), Inflammation Plaque, Atherosclerotic
NCT06710080 · CT.gov ↗
What to watch
TLL-018Phase 3
Est. primary completion 2026-12-31 · Hangzhou Highlightll Pharmaceutical · Rheumatoid Arthritis
NCT06887127 · CT.gov ↗
What to watch
Nab-paclitaxelPhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb · Glioma
NCT06330337 · CT.gov ↗
What to watch
TemozolomidePhase 3
Est. primary completion 2026-12-31 · Merck & Co. · Glioma
NCT06330337 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12-31 · Roche · Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma, Brain Tumor, Brain Tumor, Recurrent, Neoplasms, Neoplasms …
NCT06496971 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12-31 · Roche · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
NCT03303495 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-12-31 · BeOne Medicines · Advanced Cholangiocarcinoma
NCT05823311 · CT.gov ↗
GemcitabinePhase 3
Est. primary completion 2026-12-31 · Eli Lilly · Advanced Cholangiocarcinoma
NCT05823311 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2026-12-31 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Urothelial Carcinoma, HER2-expressing
NCT05302284 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3
Est. primary completion 2026-12-31 · RemeGen Co., Ltd. · Urothelial Carcinoma, HER2-expressing
NCT05302284 · CT.gov ↗
What to watch
APG-2575(Lisaftoclax )Phase 3
Est. primary completion 2026-12-31 · Ascentage Pharma Group Inc. · CLL/SLL
NCT06104566 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2026-12-31 · Takeda Pharmaceutical Company · T-cell Lymphoblastic Lymphoma
NCT05681260 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2026-12-31 · · T-cell Lymphoblastic Lymphoma
NCT05681260 · CT.gov ↗
What to watch
TelitaciceptPhase 3
Est. primary completion 2026-12-31 · ADARx Pharmaceuticals + RemeGen Co., Ltd. · Myasthenia Gravis, Ocular
NCT07249632 · CT.gov ↗
What to watch
RuxolitinibPhase 3
Est. primary completion 2026-12-31 · Incyte · Myelofibrosis
NCT06479135 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12-31 · Eli Lilly · Cervical Cancer, Cervix Cancer, Cervix Neoplasm
NCT05764044 · CT.gov ↗
What to watch
GC101Phase 3
Est. primary completion 2026-12-31 · Shanghai Juncell Therapeutics · SMA - Spinal Muscular Atrophy
NCT06971094 · CT.gov ↗
What to watch
DocetaxelPhase 3
Est. primary completion 2026-12-31 · Sanofi · Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect
NCT05813015 · CT.gov ↗
What to watch
MethylprednisolonePhase 3
Est. primary completion 2026-12-31 · Pfizer · Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
NCT05058287 · CT.gov ↗
What to watch
InavolisibPhase 3
Est. primary completion 2026-12-31 · Roche · HR+/HER2- Metastatic Breast Cancer
NCT05894239 · CT.gov ↗
What to watch
tanruprubartPhase 3
Est. primary completion 2026-12-31 · Annexon, Inc. · Guillain-Barre Syndrome
NCT07020819 · CT.gov ↗
January 2027 (66)
upadacitinib · RinvoqPhase 3
Est. primary completion 2027-01 · AbbVie · Atopic Dermatitis
NCT06701331 · CT.gov ↗
What to watch
VormatriginePhase 3
Est. primary completion 2027-01 · Praxis Precision Medicines, Inc. · Epilepsy
NCT07505004 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2027-01 · Roche · Polymyalgia Rheumatica
NCT05533164 · CT.gov ↗
What to watch
tocilizumab · Actemra / RoActemraPhase 3
Est. primary completion 2027-01 · Roche · Giant Cell Arteritis
NCT03892785 · CT.gov ↗
What to watch
Sotagliflozin (Inpefa) · InpefaPhase 3
Est. primary completion 2027-01 · Lexicon Pharmaceuticals · Hypertrophic Cardiomyopathy
NCT06481891 · CT.gov ↗
setrusumabPhase 3
Est. primary completion 2027-01 · Mereo BioPharma · Osteogenesis Imperfecta
NCT06636071 · CT.gov ↗
AzetukalnerPhase 3
Est. primary completion 2027-01 · Xenon Pharmaceuticals · Major Depressive Disorder
NCT06922110 · CT.gov ↗
What to watch
RSS0393Phase 3
Est. primary completion 2027-01 · Jiangsu Hengrui Pharmaceuticals + Reistone Biopharma · Psoriasis
NCT07543224 · CT.gov ↗
What to watch
crisaborole · EucrisaPhase 3
Est. primary completion 2027-01 · Pfizer · Atopic Dermatitis
NCT07162896 · CT.gov ↗
What to watch
Levetiracetam (Keppra) · KeppraPhase 3
Est. primary completion 2027-01 · UCB · Epilepsy
NCT07239115 · CT.gov ↗
What to watch
semaglutide · Wegovy / Ozempic / RybelsusPhase 3
Est. primary completion 2027-01 · Novo Nordisk · Diabetes Type 1
NCT06894784 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2027-01 · Boehringer Ingelheim + Eli Lilly · Diabetes Type 1
NCT06894784 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2027-01 · AstraZeneca · STEMI - ST Elevation Myocardial Infarction, Epicardial Fat
NCT07297589 · CT.gov ↗
What to watch
IvonescimabPhase 3
Est. primary completion 2027-01 · Akeso + Summit Therapeutics · Head and Neck Squamous Cell Carcinoma
NCT06601335 · CT.gov ↗
What to watch
AK117Phase 3
Est. primary completion 2027-01 · Akeso · Head and Neck Squamous Cell Carcinoma
NCT06601335 · CT.gov ↗
What to watch
LacosamidePhase 3
Est. primary completion 2027-01 · UCB · Bipolar Affective Disorder
NCT07412132 · CT.gov ↗
What to watch
Zoledronic acidPhase 3
Est. primary completion 2027-01 · Novartis · Giant Cell Tumor of Bone
NCT03295981 · CT.gov ↗
What to watch
AZD0780Phase 3
Est. primary completion 2027-01-04 · AstraZeneca · Atherosclerotic Cardiovascular Disease
NCT07000136 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3
Est. primary completion 2027-01-04 · Merck & Co. · Gastroesophageal Cancer
NCT06356311 · CT.gov ↗
What to watch
AnifrolumabPhase 3
Est. primary completion 2027-01-06 · AstraZeneca + MedImmune LLC · Systemic Sclerosis, Scleroderma
NCT05925803 · CT.gov ↗
What to watch
OTX-TKIPhase 3
Est. primary completion 2027-01-08 · OCULAR THERAPEUTIX, INC · Age-Related Macular Degeneration
NCT06495918 · CT.gov ↗
What to watch
OTX-TKI (axitinib implant)Phase 3
Est. primary completion 2027-01-08 · OCULAR THERAPEUTIX, INC · Age-Related Macular Degeneration
NCT06495918 · CT.gov ↗
What to watch
Capsaicin (Qutenza) · QutenzaPhase 3
Est. primary completion 2027-01-08 · Grünenthal GmbH + NeurogesX, Inc. (dissolved/wound down) · Coccyx Disorder, Neuropathic Pain, Coccygodynia
NCT06023706 · CT.gov ↗
What to watch
MezigdomidePhase 3
Est. primary completion 2027-01-10 · Bristol-Myers Squibb · Multiple Myeloma
NCT05519085 · CT.gov ↗
What to watch
PomalidomidePhase 3
Est. primary completion 2027-01-10 · Bristol-Myers Squibb · Multiple Myeloma
NCT05519085 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2027-01-10 · Takeda Pharmaceutical Company · Multiple Myeloma
NCT05519085 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2027-01-10 · OCULAR THERAPEUTIX, INC · Relapsed or Refractory Multiple Myeloma
NCT05519085 · CT.gov ↗
AZD0780Phase 3
Est. primary completion 2027-01-11 · AstraZeneca · Cardiovascular Disease
NCT07000123 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2027-01-11 · Cheplapharm Arzneimittel GmbH · Locally Advanced Unresectable or Metastatic Gastric Cancer …
NCT06177041 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-01-12 · Merck & Co. · Non-Small Cell Lung Cancer
NCT05609968 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3
Est. primary completion 2027-01-12 · Gilead Sciences · Non-Small Cell Lung Cancer
NCT05609968 · CT.gov ↗
What to watch
infliximab · RemicadePhase 3
Est. primary completion 2027-01-12 · Celltrion + Johnson & Johnson · Sarcoidosis
NCT05689879 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2027-01-12 · Roche · Lymphoma, Large B-Cell, Diffuse
NCT06573645 · CT.gov ↗
What to watch
EverolimusPhase 3
Est. primary completion 2027-01-13 · Novartis · Coronary Artery Disease
NCT05952206 · CT.gov ↗
What to watch
tezepelumab · TezspirePhase 3
Est. primary completion 2027-01-13 · Amgen + AstraZeneca · Chronic Rhinosinusitis With Nasal Polyps
NCT06706817 · CT.gov ↗
What to watch
IvonescimabPhase 3
Est. primary completion 2027-01-13 · Akeso + Summit Therapeutics · Colorectal Adenocarcinoma
NCT06951503 · CT.gov ↗
What to watch
sonelokimabPhase 3
Est. primary completion 2027-01-15 · MoonLake Immunotherapeutics · Psoriatic Arthritis
NCT06641089 · CT.gov ↗
What to watch
Dexmedetomidine · IgalmiPhase 3
Est. primary completion 2027-01-20 · BioXcel Therapeutics, Inc. · Cerebral Desaturation Events, Spine Surgeries
NCT06848595 · CT.gov ↗
maridebart cafraglutide · MariTidePhase 3
Est. primary completion 2027-01-21 · Amgen · Obesity
NCT06858878 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3
Est. primary completion 2027-01-21 · Amgen · Obesity
NCT06858839 · CT.gov ↗
What to watch
UblituximabPhase 3
Est. primary completion 2027-01-21 · TG THERAPEUTICS, INC. · Multiple Sclerosis
NCT05877963 · CT.gov ↗
What to watch
PumitamigPhase 3
Est. primary completion 2027-01-25 · Bristol-Myers Squibb · SCLC
NCT06616532 · CT.gov ↗
What to watch
SuzetriginePhase 3
Est. primary completion 2027-01-25 · Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
NCT06696443 · CT.gov ↗
What to watch
insulin aspart · NovoLog / FiaspPhase 3
Est. primary completion 2027-01-25 · Novo Nordisk · Diabetes Mellitus, Type 1
NCT07076199 · CT.gov ↗
What to watch
insulin icodec · AwiqliPhase 3
Est. primary completion 2027-01-25 · Novo Nordisk · Diabetes Mellitus, Type 1
NCT07076199 · CT.gov ↗
What to watch
fluticasone furoate/umeclidinium/vilanterol · Trelegy ElliptaPhase 3
Est. primary completion 2027-01-26 · GlaxoSmithKline · Asthma
NCT05757102 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 3
Est. primary completion 2027-01-28 · Novartis · HR+/HER2- Metastatic Breast Cancer
NCT05038735 · CT.gov ↗
What to watch
Fulvestrant · FaslodexPhase 3
Est. primary completion 2027-01-28 · AstraZeneca · HR+/HER2- Metastatic Breast Cancer
NCT05038735 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-01-29 · Merck & Co. · Urothelial Carcinoma
NCT05911295 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3
Est. primary completion 2027-01-29 · RemeGen Co., Ltd. · Urothelial Carcinoma
NCT05911295 · CT.gov ↗
What to watch
ZiltivekimabPhase 3
Est. primary completion 2027-01-29 · Novo Nordisk · Cardiovascular Risk, Acute Myocardial Infarction (AMI)
NCT06118281 · CT.gov ↗
What to watch
Iptacopan · FabhaltaPhase 3
Est. primary completion 2027-01-29 · Novartis · C3G
NCT04817618 · CT.gov ↗
What to watch
afimkibartPhase 3
Est. primary completion 2027-01-30 · Pfizer + Roche · Ulcerative Colitis
NCT06589986 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2027-01-30 · BeOne Medicines · Lung Cancer (NSCLC)
NCT06598527 · CT.gov ↗
PembrolizumabPhase 3
Est. primary completion 2027-01-31 · Merck & Co. · Urinary Bladder Neoplasms
NCT04241185 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2027-01-31 · Eli Lilly · Urinary Bladder Neoplasms
NCT04241185 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2027-01-31 · Roche · Chronic Lymphocytic Leukemia
NCT03836261 · CT.gov ↗
VenetoclaxPhase 3
Est. primary completion 2027-01-31 · Roche · Acute T Lymphoblastic Leukemia (T-ALL)
NCT07541755 · CT.gov ↗
RituximabPhase 3
Est. primary completion 2027-01-31 · Roche · Mantle Cell Lymphoma
NCT03267433 · CT.gov ↗
What to watch
Cenobamate · XcopriPhase 3
Est. primary completion 2027-01-31 · SK Biopharmaceuticals Co., Ltd. · Epilepsy
NCT06579573 · CT.gov ↗
What to watch
MethylprednisolonePhase 3
Est. primary completion 2027-01-31 · Pfizer · Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial
NCT05139849 · CT.gov ↗
What to watch
Macitentan · OpsumitPhase 3
Est. primary completion 2027-01-31 · Johnson & Johnson · Hypertension, Pulmonary
NCT05179876 · CT.gov ↗
What to watch
Tadalafil · AdcircaPhase 3
Est. primary completion 2027-01-31 · Eli Lilly · Hypertension
NCT05179876 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-01-31 · Merck & Co. · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma …
NCT04267848 · CT.gov ↗
What to watch
pemetrexed · AlimtaPhase 3
Est. primary completion 2027-01-31 · Eli Lilly · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma …
NCT04267848 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2027-01-31 · Eli Lilly · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma …
NCT04267848 · CT.gov ↗
What to watch
February 2027 (47)
CT-P51Phase 3
Est. primary completion 2027-02 · Celltrion · Non-Small Cell Lung Cancer
NCT06939595 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-02 · Merck & Co. · Triple Negative Breast Cancer, PD-L1 Positive
NCT05382286 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3
Est. primary completion 2027-02 · Gilead Sciences · Triple Negative Breast Cancer, PD-L1 Positive
NCT05382286 · CT.gov ↗
What to watch
Aflibercept · EyleaPhase 3
Est. primary completion 2027-02 · Amgen + Biocon + Celltrion + Formycon AG + Harrow, Inc. + Regeneron Pharmaceuticals + Sandoz Group AG · Age-Related Macular Degeneration
NCT07129239 · CT.gov ↗
What to watch
stapokibartPhase 3
Est. primary completion 2027-02 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. + Keymed Biosciences · Atopic Dermatitis
NCT07106372 · CT.gov ↗
What to watch
difamilast · Moizerto / AdqueyPhase 3
Est. primary completion 2027-02 · Acrotech Biopharma + Otsuka Holdings · Atopic Dermatitis
NCT07184645 · CT.gov ↗
What to watch
CT-P53Phase 3
Est. primary completion 2027-02 · Celltrion · Multiple Sclerosis
NCT05906992 · CT.gov ↗
What to watch
KSI-101Phase 3
Est. primary completion 2027-02 · Kodiak Sciences Inc. · Macular Edema Secondary to Inflammation
NCT06996080 · CT.gov ↗
What to watch
CarisbamatePhase 3
Est. primary completion 2027-02 · SK Biopharmaceuticals Co., Ltd. · Epilepsy
NCT05219617 · CT.gov ↗
What to watch
ribupatidePhase 3
Est. primary completion 2027-02 · Jiangsu Hengrui Pharmaceuticals + Kailera Therapeutics · Type 2 Diabetes
NCT07060456 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2027-02 · Roche · Acute Myeloid Leukemia
NCT05183035 · CT.gov ↗
AzacitidinePhase 3
Est. primary completion 2027-02 · Bristol-Myers Squibb · Acute Myeloid Leukemia
NCT05183035 · CT.gov ↗
What to watch
Gemtuzumab OzogamicinPhase 3
Est. primary completion 2027-02 · Pfizer · Acute Myeloid Leukemia
NCT05183035 · CT.gov ↗
What to watch
ElismetrepPhase 3
Est. primary completion 2027-02 · Kallyope · Migraine
NCT07645924 · CT.gov ↗
orforglipron · FoundayoPhase 3
Est. primary completion 2027-02 · Eli Lilly · Obesity
NCT06672549 · CT.gov ↗
What to watch
TQC3721Phase 3
Est. primary completion 2027-02 · Sino Biopharmaceutical · Chronic Obstructive Pulmonary Disease
NCT07464587 · CT.gov ↗
What to watch
LetrozolePhase 3
Est. primary completion 2027-02-01 · Novartis · Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma …
NCT04095364 · CT.gov ↗
What to watch
ApatinibPhase 3
Est. primary completion 2027-02-01 · Jiangsu Hengrui Pharmaceuticals · Advanced Breast Cancer, HR+/HER2- Breast Cancer
NCT06447623 · CT.gov ↗
What to watch
Fulvestrant · FaslodexPhase 3
Est. primary completion 2027-02-01 · AstraZeneca · HR+/HER2- Metastatic Breast Cancer
NCT06447623 · CT.gov ↗
What to watch
Montelukast (Singulair)Phase 3
Est. primary completion 2027-02-01 · Organon · Myocardial Infarction (MI)
NCT07320625 · CT.gov ↗
What to watch
Levosimendan · SimdaxPhase 3
Est. primary completion 2027-02-03 · Orion Corporation + Tenax Therapeutics · Cardiogenic Shock
NCT04020263 · CT.gov ↗
What to watch
Ranibizumab · LucentisPhase 3
Est. primary completion 2027-02-04 · Harrow, Inc. + Lupin Limited + Roche + Sandoz Group AG + Zydus Lifesciences · Age-Related Macular Degeneration
NCT04657289 · CT.gov ↗
What to watch
sonelokimabPhase 3
Est. primary completion 2027-02-04 · MoonLake Immunotherapeutics · Psoriatic Arthritis
NCT06641076 · CT.gov ↗
What to watch
guselkumab · TremfyaPhase 3
Est. primary completion 2027-02-10 · Johnson & Johnson · Ulcerative Colitis
NCT06260163 · CT.gov ↗
What to watch
icotrokinraPhase 3
Est. primary completion 2027-02-10 · Johnson & Johnson + Protagonist Therapeutics · Arthritis, Psoriatic
NCT06807424 · CT.gov ↗
What to watch
Inclisiran · LeqvioPhase 3
Est. primary completion 2027-02-11 · Alnylam Pharmaceuticals + Novartis · Atherosclerotic Cardiovascular Disease
NCT07102628 · CT.gov ↗
What to watch
LenalidomidePhase 3
Est. primary completion 2027-02-13 · Bristol-Myers Squibb + Celgene Corporation · Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
NCT04224493 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2027-02-13 · Roche · Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
NCT04224493 · CT.gov ↗
What to watch
tirzepatide · Zepbound / MounjaroPhase 3
Est. primary completion 2027-02-14 · Eli Lilly · Obesity, Type 2 Diabetes
NCT07481747 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2027-02-15 · Roche · Lymphoma, Mantle Cell
NCT02972840 · CT.gov ↗
What to watch
RepotrectinibPhase 3
Est. primary completion 2027-02-16 · Bristol-Myers Squibb · Non-Small Cell Lung Cancer
NCT06140836 · CT.gov ↗
HDM1002Phase 3
Est. primary completion 2027-02-16 · Hangzhou Zhongmei Huadong Pharmaceutical · Type 2 Diabetes
NCT07082114 · CT.gov ↗
What to watch
itepekimabPhase 3
Est. primary completion 2027-02-17 · Regeneron Pharmaceuticals + Sanofi · Chronic Rhinosinusitis With Nasal Polyps
NCT07424144 · CT.gov ↗
What to watch
Zibotentan + DapagliflozinPhase 3
Est. primary completion 2027-02-18 · AstraZeneca · Chronic Kidney Disease With High Proteinuria
NCT06087835 · CT.gov ↗
GemcitabinePhase 3
Est. primary completion 2027-02-20 · Eli Lilly · Nasopharyngeal Carcinoma
NCT06239727 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2027-02-20 · Cheplapharm Arzneimittel GmbH · Nasopharyngeal Carcinoma
NCT06239727 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 3
Est. primary completion 2027-02-22 · AstraZeneca · Cancer
NCT05629234 · CT.gov ↗
RituximabPhase 3
Est. primary completion 2027-02-22 · Roche · Diffuse Large B-Cell Lymphoma
NCT04529772 · CT.gov ↗
What to watch
AnifrolumabPhase 3
Est. primary completion 2027-02-23 · AstraZeneca + MedImmune LLC · Systemic Lupus Erythematosus
NCT05138133 · CT.gov ↗
What to watch
SuzetriginePhase 3
Est. primary completion 2027-02-23 · Vertex Pharmaceuticals · Total Knee Replacement Surgery, Post-operative Pain
NCT07548385 · CT.gov ↗
What to watch
IncobotulinumtoxinA (Xeomin, PD sialorrhea) · XeominPhase 3
Est. primary completion 2027-02-24 · Merz Pharmaceuticals · Chronic Migraine
NCT05598723 · CT.gov ↗
What to watch
Abemaciclib · VerzenioPhase 3
Est. primary completion 2027-02-25 · Eli Lilly · HR+/HER2- Metastatic Breast Cancer
NCT06341621 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 3
Est. primary completion 2027-02-26 · Novartis · Advanced HER2+Breast Cancer
NCT04208178 · CT.gov ↗
What to watch
Tenapanor · Xphozah / IbsrelaPhase 3
Est. primary completion 2027-02-26 · Ardelyx · Chronic Idiopathic Constipation (CIC)
NCT07382167 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2027-02-28 · · Intermittent Claudication
NCT05132439 · CT.gov ↗
What to watch
Tadalafil · AdcircaPhase 3
Est. primary completion 2027-02-28 · Eli Lilly · Prostate Carcinoma, Erectile Function, Genito Urinary Cancer
NCT06717711 · CT.gov ↗
What to watch
Somatropin · SerostimPhase 3
Est. primary completion 2027-02-28 · EMD Serono · Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
NCT04867317 · CT.gov ↗
What to watch
March 2027 (63)
risankizumab · SkyriziPhase 3
Est. primary completion 2027-03 · AbbVie · Crohn's Disease
NCT06063967 · CT.gov ↗
What to watch
ribupatidePhase 3
Est. primary completion 2027-03 · Jiangsu Hengrui Pharmaceuticals + Kailera Therapeutics · Obesity
NCT07285902 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3
Est. primary completion 2027-03 · AbbVie · Systemic Lupus Erythematosus
NCT05843643 · CT.gov ↗
What to watch
baricitinib · OlumiantPhase 3
Est. primary completion 2027-03 · Eli Lilly · Rheumatoid Arthritis
NCT04870203 · CT.gov ↗
What to watch
Olezarsen · TryngolzaPhase 3
Est. primary completion 2027-03 · Ionis Pharmaceuticals · Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
NCT05681351 · CT.gov ↗
What to watch
Resmetirom · RezdiffraPhase 3
Est. primary completion 2027-03 · Madrigal Pharmaceuticals · MASH / NASH
NCT04951219 · CT.gov ↗
What to watch
EpirubicinPhase 3
Est. primary completion 2027-03 · Pfizer · HR+/HER2- Metastatic Breast Cancer
NCT02455141 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2027-03 · Roche · Severe Forms of Mucous Membrane Pemphigoid
NCT03295383 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2027-03 · Roche · Diffuse Large B-cell Lymphoma
NCT06929624 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2027-03 · Eli Lilly · Diffuse Large B-cell Lymphoma
NCT06929624 · CT.gov ↗
What to watch
TQC3721Phase 3
Est. primary completion 2027-03 · Sino Biopharmaceutical · Chronic Obstructive Pulmonary Disease
NCT07147946 · CT.gov ↗
What to watch
QLM3003Phase 3
Est. primary completion 2027-03 · Qilu Pharmaceutical · Atopic Dermatitis
NCT06880276 · CT.gov ↗
What to watch
Bemdaneprocel (MSK-DA01)Phase 3
Est. primary completion 2027-03 · BlueRock Therapeutics · Parkinson's Disease
NCT06944522 · CT.gov ↗
What to watch
Cariprazine (Vraylar) · VraylarPhase 3
Est. primary completion 2027-03 · AbbVie + Gedeon Richter + Tanabe Pharma Corporation · Depression, Bipolar I Disorder
NCT04777357 · CT.gov ↗
What to watch
OTX-TKI (axitinib implant)Phase 3
Est. primary completion 2027-03 · OCULAR THERAPEUTIX, INC · Non-Proliferative Diabetic Retinopathy
NCT07235085 · CT.gov ↗
What to watch
ZorevunersenPhase 3
Est. primary completion 2027-03 · Stoke Therapeutics, Inc. · Dravet Syndrome
NCT06872125 · CT.gov ↗
Tretinoin · VesanoidPhase 3
Est. primary completion 2027-03 · Cheplapharm Arzneimittel GmbH + Roche · Acute Myeloid Leukemia
NCT07504458 · CT.gov ↗
What to watch
QTX-2101Phase 3
Est. primary completion 2027-03 · Quetzal Therapeutics · Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA …
NCT07504458 · CT.gov ↗
What to watch
IncobotulinumtoxinA (Xeomin, PD sialorrhea) · XeominPhase 3
Est. primary completion 2027-03 · Merz Pharmaceuticals · Episodic Migraine
NCT07018700 · CT.gov ↗
What to watch
cagrilintide/semaglutide · CagriSemaPhase 3
Est. primary completion 2027-03-01 · Novo Nordisk · Obesity
NCT07011667 · CT.gov ↗
What to watch
UtidelonePhase 3
Est. primary completion 2027-03-01 · Beijing Biostar Pharmaceuticals · HR+/HER2- Metastatic Breast Cancer
NCT05172518 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2027-03-01 · Cheplapharm Arzneimittel GmbH · HR+/HER2- Metastatic Breast Cancer
NCT05172518 · CT.gov ↗
What to watch
DepemokimabPhase 3
Est. primary completion 2027-03-01 · GlaxoSmithKline · Asthma
NCT07671001 · CT.gov ↗
What to watch
RecaticimabPhase 3
Est. primary completion 2027-03-01 · Jiangsu Hengrui Pharmaceuticals · Stroke
NCT07002476 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2027-03-01 · · B Acute Lymphoblastic Leukemia
NCT03150693 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2027-03-01 · Roche · B Acute Lymphoblastic Leukemia
NCT03150693 · CT.gov ↗
What to watch
bimekizumab · BimzelxPhase 3
Est. primary completion 2027-03-09 · UCB · Psoriatic Arthritis, Psoriasis
NCT06506916 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2027-03-11 · Bristol-Myers Squibb · Renal Cell Carcinoma
NCT03873402 · CT.gov ↗
What to watch
IpilimumabPhase 3
Est. primary completion 2027-03-11 · Bristol-Myers Squibb · Renal Cell Carcinoma
NCT03873402 · CT.gov ↗
What to watch
setmelanotide · ImcivreePhase 3
Est. primary completion 2027-03-13 · Rhythm Pharmaceuticals · Obesity, Hypothalamic Obesity
NCT06760546 · CT.gov ↗
What to watch
GoserelinPhase 3
Est. primary completion 2027-03-15 · AstraZeneca + TerSera Therapeutics LLC · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …
NCT04455750 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2027-03-16 · Boehringer Ingelheim + Eli Lilly · Cardiogenic Shock
NCT05879276 · CT.gov ↗
What to watch
tofacitinib · XeljanzPhase 3
Est. primary completion 2027-03-17 · Pfizer · Ulcerative Colitis
NCT04624230 · CT.gov ↗
What to watch
RituximabPhase 3
Est. primary completion 2027-03-18 · Roche · Marginal Zone Lymphoma
NCT04212013 · CT.gov ↗
What to watch
roflumilast · ZoryvePhase 3
Est. primary completion 2027-03-20 · Arcutis Biotherapeutics · Depressive Disorder, Major
NCT06860958 · CT.gov ↗
What to watch
Olanzapine (Zyprexa) · ZyprexaPhase 3
Est. primary completion 2027-03-20 · Cheplapharm Arzneimittel GmbH + Eli Lilly · Advanced Cancer, Olanzapine, Progression Free Survival
NCT06338683 · CT.gov ↗
What to watch
CemiplimabPhase 3
Est. primary completion 2027-03-22 · Regeneron Pharmaceuticals + Sanofi · Melanoma
NCT06246916 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2027-03-23 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · HR+/HER2- Breast Cancer
NCT06977893 · CT.gov ↗
What to watch
Fitusiran · QfitliaPhase 3
Est. primary completion 2027-03-25 · Alnylam Pharmaceuticals · Hemophilia
NCT05662319 · CT.gov ↗
guselkumab · TremfyaPhase 3
Est. primary completion 2027-03-25 · Johnson & Johnson · Crohn's Disease
NCT05347095 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 3
Est. primary completion 2027-03-26 · AstraZeneca · Non-Small Cell Lung Cancer
NCT06380348 · CT.gov ↗
JMT101Phase 3
Est. primary completion 2027-03-26 · Shanghai JMT-Bio · Non-Small Cell Lung Cancer
NCT06380348 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3
Est. primary completion 2027-03-30 · Gilead Sciences · HER2-negative Breast Cancer, Triple Negative Breast Cancer
NCT04595565 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2027-03-30 · Cheplapharm Arzneimittel GmbH · HER2-negative Breast Cancer, Triple Negative Breast Cancer
NCT04595565 · CT.gov ↗
What to watch
HS-20094Phase 3
Est. primary completion 2027-03-30 · Hansoh Pharmaceutical Group · Type 2 Diabetes
NCT07156539 · CT.gov ↗
What to watch
HS-20094Phase 3
Est. primary completion 2027-03-30 · Hansoh Pharmaceutical Group · Type 2 Diabetes
NCT07156500 · CT.gov ↗
What to watch
Ferric derisomaltose · Monoferric / MonoferPhase 3
Est. primary completion 2027-03-30 · Pharmacosmos · Iron Deficiency Anemia, Pregnancy
NCT05462704 · CT.gov ↗
What to watch
BinimetinibPhase 3
Est. primary completion 2027-03-31 · Pfizer · Melanoma
NCT05270044 · CT.gov ↗
What to watch
EncorafenibPhase 3
Est. primary completion 2027-03-31 · Pfizer · Melanoma
NCT05270044 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2027-03-31 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Gastric or Esophagogastric Junction Adenocarcinoma
NCT05180734 · CT.gov ↗
What to watch
AtezolizumabPhase 3
Est. primary completion 2027-03-31 · Roche · Breast Cancer
NCT04873362 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2027-03-31 · Bristol-Myers Squibb · Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma …
NCT04444921 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2027-03-31 · Eli Lilly · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma …
NCT03533582 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2027-03-31 · Bristol-Myers Squibb · Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
NCT03391869 · CT.gov ↗
What to watch
IpilimumabPhase 3
Est. primary completion 2027-03-31 · Bristol-Myers Squibb · Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
NCT03391869 · CT.gov ↗
What to watch
HS-20137Phase 3
Est. primary completion 2027-03-31 · Hansoh Pharmaceutical Group · Psoriasis
NCT06844799 · CT.gov ↗
What to watch
PomalidomidePhase 3
Est. primary completion 2027-03-31 · Bristol-Myers Squibb · Multiple Myeloma
NCT06508983 · CT.gov ↗
What to watch
SG301Phase 3
Est. primary completion 2027-03-31 · Hangzhou Sumgen Biotech Co., Ltd. · Multiple Myeloma
NCT06508983 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2027-03-31 · OCULAR THERAPEUTIX, INC · Relapsed/Refractory Multiple Myeloma
NCT06508983 · CT.gov ↗
liraglutide · Saxenda / VictozaPhase 3
Est. primary completion 2027-03-31 · Novo Nordisk · Delirium, Postoperative
NCT06361238 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2027-03-31 · · Obesity and Cardiovascular Risk, Insulin Resistance, Obesity (Body Mass Index >30 kg/m2)
NCT07297290 · CT.gov ↗
What to watch
Neovasculgen · NeovasculgenPhase 3
Est. primary completion 2027-03-31 · Artgen Biotech · Ulcer Foot, Mellitus Diabetes
NCT07391319 · CT.gov ↗
What to watch
OlverembatinibPhase 3
Est. primary completion 2027-03-31 · Ascentage Pharma Group Inc. · GIST
NCT06640361 · CT.gov ↗
What to watch

Upcoming earnings

Expected report dates from the sourced earnings calendar (US-listed companies only; no forward date is sourced for foreign-only listings). Dates can and do move before the report.

  • 2026-10-08Nurix Therapeutics, Inc.period ending 2026-08-31
  • 2026-10-13Johnson & Johnsonperiod ending 2026-09-30
  • 2026-10-15Pulmatrixperiod ending 2026-09-30
  • 2026-10-19Summit Therapeuticsperiod ending 2026-09-30
  • 2026-10-22AB Scienceperiod ending 2026-09-30
  • 2026-10-22PharmaMarperiod ending 2026-09-30
  • 2026-10-23Dr. Reddy's Laboratoriesperiod ending 2026-09-30
  • 2026-10-26BioMarin Pharmaceuticalperiod ending 2026-09-30
  • 2026-10-27Alkermes plcperiod ending 2026-09-30
  • 2026-10-27Arcus Biosciencesperiod ending 2026-09-30
  • 2026-10-27Arcutis Biotherapeuticsperiod ending 2026-09-30
  • 2026-10-27Incyteperiod ending 2026-09-30
  • 2026-10-27Neurocrine Biosciencesperiod ending 2026-09-30
  • 2026-10-27Novartisperiod ending 2026-09-30
  • 2026-10-28Biogenperiod ending 2026-09-30 · pre-market
  • 2026-10-28GlaxoSmithKlineperiod ending 2026-09-30 · pre-market
  • 2026-10-28Viking Therapeuticsperiod ending 2026-09-30
  • 2026-10-29AGIOS PHARMACEUTICALS, INC.period ending 2026-09-30
  • 2026-10-29Alnylam Pharmaceuticalsperiod ending 2026-09-30
  • 2026-10-29Amneal Pharmaceuticalsperiod ending 2026-09-30
  • 2026-10-29Ardelyxperiod ending 2026-09-30
  • 2026-10-29BicycleTx Limitedperiod ending 2026-09-30
  • 2026-10-29Bristol-Myers Squibbperiod ending 2026-09-30
  • 2026-10-29Eli Lillyperiod ending 2026-09-30
  • 2026-10-29Gilead Sciencesperiod ending 2026-09-30
  • 2026-10-29INmune Bioperiod ending 2026-09-30
  • 2026-10-29Indivior Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-10-29Merck & Co.period ending 2026-09-30
  • 2026-10-29Molecular Partnersperiod ending 2026-09-30
  • 2026-10-29Takeda Pharmaceutical Companyperiod ending 2026-09-30
  • 2026-10-30ABVC BioPharmaperiod ending 2026-09-30
  • 2026-10-30AbbVieperiod ending 2026-09-30
  • 2026-10-30AstraZenecaperiod ending 2026-09-30 · pre-market
  • 2026-10-30Regeneron Pharmaceuticalsperiod ending 2026-09-30 · pre-market
  • 2026-10-30Sanofiperiod ending 2026-09-30 · pre-market
  • 2026-11-02Axsome Therapeuticsperiod ending 2026-09-30
  • 2026-11-02Karyopharm Therapeuticsperiod ending 2026-09-30
  • 2026-11-02Krystal Biotech, Inc.period ending 2026-09-30
  • 2026-11-02Liquidia Corporationperiod ending 2026-09-30
  • 2026-11-02Nuvation Bioperiod ending 2026-09-30
  • 2026-11-02PRECISION BIOSCIENCES INCperiod ending 2026-09-30
  • 2026-11-02Pyxis Oncologyperiod ending 2026-09-30
  • 2026-11-02Seaport Therapeuticsperiod ending 2026-09-30
  • 2026-11-02Syndaxperiod ending 2026-09-30
  • 2026-11-02TG THERAPEUTICS, INC.period ending 2026-09-30
  • 2026-11-02Vertex Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-02Xenon Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-03AC Immuneperiod ending 2026-09-30
  • 2026-11-03Amgenperiod ending 2026-09-30
  • 2026-11-03AnaptysBioperiod ending 2026-09-30
  • 2026-11-03Aurinia Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-03Beam Therapeutics Inc.period ending 2026-09-30
  • 2026-11-03BioNTechperiod ending 2026-09-30 · pre-market
  • 2026-11-03Biomea Fusionperiod ending 2026-09-30
  • 2026-11-03COMPASS Pathwaysperiod ending 2026-09-30
  • 2026-11-03Corcept Therapeuticsperiod ending 2026-09-30
  • 2026-11-03Corvus Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-03Cumberland Pharmaceuticals Inc.period ending 2026-09-30
  • 2026-11-03Exelixisperiod ending 2026-09-30
  • 2026-11-03Harmony Biosciencesperiod ending 2026-09-30
  • 2026-11-03IDEAYA Biosciencesperiod ending 2026-09-30
  • 2026-11-03ImmunityBioperiod ending 2026-09-30
  • 2026-11-03Kura Oncology, Inc.period ending 2026-09-30
  • 2026-11-03Kymera Therapeuticsperiod ending 2026-09-30
  • 2026-11-03Longeveron (NASDAQ: LGVN)period ending 2026-09-30
  • 2026-11-03Madrigal Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-03Mirum Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-03Nuvectis Pharmaperiod ending 2026-09-30
  • 2026-11-03OCULAR THERAPEUTIX, INCperiod ending 2026-09-30
  • 2026-11-03PTC Therapeuticsperiod ending 2026-09-30
  • 2026-11-03Pfizerperiod ending 2026-09-30
  • 2026-11-03Rhythm Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-03Rigel Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-03Spyre Therapeuticsperiod ending 2026-09-30
  • 2026-11-03Stoke Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-03Supernus Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-03Tango Therapeuticsperiod ending 2026-09-30
  • 2026-11-03Teva Pharmaceutical Industriesperiod ending 2026-09-30 · pre-market
  • 2026-11-03Verastem, Inc.period ending 2026-09-30
  • 2026-11-03Werewolf Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-04Acadia Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-04Aldeyra Therapeuticsperiod ending 2026-09-30
  • 2026-11-04Amarin Corporationperiod ending 2026-09-30
  • 2026-11-04Aquestive Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-04Arvinas Inc.period ending 2026-09-30
  • 2026-11-04Bausch Healthperiod ending 2026-09-30
  • 2026-11-04Compass Therapeuticsperiod ending 2026-09-30
  • 2026-11-04Cytokineticsperiod ending 2026-09-30
  • 2026-11-04Emergent BioSolutionsperiod ending 2026-09-30
  • 2026-11-04Foghorn Therapeutics Inc.period ending 2026-09-30
  • 2026-11-04Fulcrum Therapeuticsperiod ending 2026-09-30
  • 2026-11-04Genelux Corporationperiod ending 2026-09-30
  • 2026-11-04Geron Corporationperiod ending 2026-09-30
  • 2026-11-04Gossamer Bioperiod ending 2026-09-30
  • 2026-11-04Ionis Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-04Jazz Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-04Lexeo Therapeuticsperiod ending 2026-09-30
  • 2026-11-04MannKind Corporationperiod ending 2026-09-30
  • 2026-11-04Minerva Neurosciencesperiod ending 2026-09-30
  • 2026-11-04MoonLake Immunotherapeuticsperiod ending 2026-09-30
  • 2026-11-04NewAmsterdam Pharmaperiod ending 2026-09-30
  • 2026-11-04NextCure, Inc.period ending 2026-09-30
  • 2026-11-04Novo Nordiskperiod ending 2026-09-30
  • 2026-11-04OPKO Healthperiod ending 2026-09-30
  • 2026-11-04Praxis Precision Medicines, Inc.period ending 2026-09-30
  • 2026-11-04Recursion Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-04Revolution Medicinesperiod ending 2026-09-30
  • 2026-11-04Seres Therapeuticsperiod ending 2026-09-30
  • 2026-11-04Tempest Therapeuticsperiod ending 2026-09-30
  • 2026-11-04United Therapeuticsperiod ending 2026-09-30
  • 2026-11-04Upstream Bioperiod ending 2026-09-30
  • 2026-11-04Vanda Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-04Vir Biotechnologyperiod ending 2026-09-30
  • 2026-11-04Xencorperiod ending 2026-09-30
  • 2026-11-05Aclaris Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Alectorperiod ending 2026-09-30
  • 2026-11-05Aligos Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Allogene Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05Altimmuneperiod ending 2026-09-30
  • 2026-11-05Amphastar Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-05Amylyx Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-05Aptevo Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Avalo Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05BeOne Medicinesperiod ending 2026-09-30
  • 2026-11-05Black Diamond Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05C4 Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05Cartesian Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05Climb Bio, Inc.period ending 2026-09-30
  • 2026-11-05Cognition Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Coherus BioSciences, Inc.period ending 2026-09-30
  • 2026-11-05Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, acquired 2022)period ending 2026-09-30
  • 2026-11-05Cullinan Therapeutics Inc.period ending 2026-09-30
  • 2026-11-05Curisperiod ending 2026-09-30
  • 2026-11-05Definium Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Denali Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Disc Medicineperiod ending 2026-09-30
  • 2026-11-05GH Researchperiod ending 2026-09-30
  • 2026-11-05Genmabperiod ending 2026-09-30
  • 2026-11-05GlycoMimetics, Inc. (renamed Crescent Biopharma, Inc., June 2025)period ending 2026-09-30
  • 2026-11-05Immunocore Holdings plcperiod ending 2026-09-30
  • 2026-11-05Immunome, Inc.period ending 2026-09-30
  • 2026-11-05Iovance Biotherapeuticsperiod ending 2026-09-30
  • 2026-11-05Janux Therapeuticsperiod ending 2026-09-30
  • 2026-11-05LB Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-05Lexicon Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-05Ligand Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-05Lipocine Inc.period ending 2026-09-30
  • 2026-11-05Lisata Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Maze Therapeuticsperiod ending 2026-09-30
  • 2026-11-05MetaViaperiod ending 2026-09-30
  • 2026-11-05Modernaperiod ending 2026-09-30
  • 2026-11-05Monte Rosa Therapeutics, Incperiod ending 2026-09-30
  • 2026-11-05Nektar Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Neumora Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05Pliant Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05Processa Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-05Protagonist Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Prothena Biosciences Limitedperiod ending 2026-09-30
  • 2026-11-05Puma Biotechnologyperiod ending 2026-09-30
  • 2026-11-05RANI Therapeuticsperiod ending 2026-09-30
  • 2026-11-05REGENXBIO Inc.period ending 2026-09-30
  • 2026-11-05Rapport Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05Relay Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05Replimune, Inc.period ending 2026-09-30
  • 2026-11-05Shattuck Labs, Inc.period ending 2026-09-30
  • 2026-11-05Silence Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Structure Therapeuticsperiod ending 2026-09-30
  • 2026-11-05Sutro Biopharma, Inc.period ending 2026-09-30
  • 2026-11-05Tectonic Therapeuticperiod ending 2026-09-30
  • 2026-11-05Vericel Corporationperiod ending 2026-09-30
  • 2026-11-05Viatrisperiod ending 2026-09-30
  • 2026-11-05Whitehawk Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-05Zai Labperiod ending 2026-09-30
  • 2026-11-05Zymeworksperiod ending 2026-09-30
  • 2026-11-05vTv Therapeuticsperiod ending 2026-09-30
  • 2026-11-06ALX Oncology Inc.period ending 2026-09-30
  • 2026-11-06ANI Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-06CervoMed Inc.period ending 2026-09-30
  • 2026-11-06Cogent Biosciences, Inc.period ending 2026-09-30
  • 2026-11-06Gyre Therapeuticsperiod ending 2026-09-30
  • 2026-11-06Kiora Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-06Soligenixperiod ending 2026-09-30
  • 2026-11-09ARS Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-09Agenus Inc.period ending 2026-09-30
  • 2026-11-09Akebia Therapeuticsperiod ending 2026-09-30
  • 2026-11-09Annexon, Inc.period ending 2026-09-30
  • 2026-11-09Assembly Biosciencesperiod ending 2026-09-30
  • 2026-11-09BioVie Inc. (NASDAQ: BIVI)period ending 2026-09-30
  • 2026-11-09Biohavenperiod ending 2026-09-30
  • 2026-11-09COMPUGEN LTDperiod ending 2026-09-30
  • 2026-11-09CRISPR Therapeuticsperiod ending 2026-09-30
  • 2026-11-09Capricor Therapeuticsperiod ending 2026-09-30
  • 2026-11-09Celldex Therapeuticsperiod ending 2026-09-30
  • 2026-11-09Editas Medicine, Inc.period ending 2026-09-30
  • 2026-11-09Harrow, Inc.period ending 2026-09-30
  • 2026-11-09Inovio Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-09Ironwood Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-09Jasper Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-09Kyntra Bioperiod ending 2026-09-30
  • 2026-11-09Matinas BioPharmaperiod ending 2026-09-30
  • 2026-11-09Mereo BioPharmaperiod ending 2026-09-30
  • 2026-11-09Mineralys Therapeuticsperiod ending 2026-09-30
  • 2026-11-09Olema Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-09Organonperiod ending 2026-09-30
  • 2026-11-09Palisade Bioperiod ending 2026-09-30
  • 2026-11-09ProKidneyperiod ending 2026-09-30
  • 2026-11-09Protara Therapeuticsperiod ending 2026-09-30
  • 2026-11-09Roivant Sciences Ltd.period ending 2026-09-30
  • 2026-11-09Skye Bioscienceperiod ending 2026-09-30
  • 2026-11-09Theravance Biopharmaperiod ending 2026-09-30
  • 2026-11-09Tonix Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-09Voyager Therapeuticsperiod ending 2026-09-30
  • 2026-11-09Wave Life Sciencesperiod ending 2026-09-30
  • 2026-11-09uniQureperiod ending 2026-09-30
  • 2026-11-10Kardiganperiod ending 2026-09-30
  • 2026-11-11ATOSSA THERAPEUTICS, INC.period ending 2026-09-30
  • 2026-11-11Acumen Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-11Alto Neuroscienceperiod ending 2026-09-30
  • 2026-11-11Alvotechperiod ending 2026-09-30
  • 2026-11-11Annovis Bio (NYSE American: ANVS)period ending 2026-09-30
  • 2026-11-11Ascendis Pharma Oncology Division A/Speriod ending 2026-09-30
  • 2026-11-11Autolus Therapeutics plcperiod ending 2026-09-30
  • 2026-11-11Avalyn Pharma Inc.period ending 2026-09-30
  • 2026-11-11BeyondSpring Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-11BioCardiaperiod ending 2026-09-30
  • 2026-11-11Caribou Biosciences, Inc.period ending 2026-09-30
  • 2026-11-11Celcuity Inc.period ending 2026-09-30
  • 2026-11-11Connect Biopharmaperiod ending 2026-09-30
  • 2026-11-11CorMedixperiod ending 2026-09-30
  • 2026-11-11Corbus Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-11DiaMedica Therapeuticsperiod ending 2026-09-30
  • 2026-11-11Enliven Therapeuticsperiod ending 2026-09-30
  • 2026-11-11Erascaperiod ending 2026-09-30
  • 2026-11-11Humacyteperiod ending 2026-09-30
  • 2026-11-11Immuneering Corporationperiod ending 2026-09-30
  • 2026-11-11Indaptus Therapeutics, Incperiod ending 2026-09-30
  • 2026-11-11Inmagene Biopharmaceuticalsperiod ending 2026-09-30
  • 2026-11-11Kailera Therapeuticsperiod ending 2026-09-30
  • 2026-11-11Lantern Pharma Inc.period ending 2026-09-30
  • 2026-11-11Legend Biotech Corporationperiod ending 2026-09-30
  • 2026-11-11Lyell Immunopharma, Inc.period ending 2026-09-30
  • 2026-11-11MacroGenicsperiod ending 2026-09-30
  • 2026-11-11MediciNova, Inc.period ending 2026-09-30
  • 2026-11-11Oncolytics Biotech Inc.period ending 2026-09-30
  • 2026-11-11Opus Genetics, Inc.period ending 2026-09-30
  • 2026-11-11Oruka Therapeuticsperiod ending 2026-09-30
  • 2026-11-11PMV Pharmaceuticals, Incperiod ending 2026-09-30
  • 2026-11-11Pluri Inc.period ending 2026-09-30
  • 2026-11-11Prelude Therapeuticsperiod ending 2026-09-30
  • 2026-11-11ProMIS Neurosciences, Inc.period ending 2026-09-30
  • 2026-11-11Quince Therapeuticsperiod ending 2026-09-30
  • 2026-11-11Rockwell Medicalperiod ending 2026-09-30
  • 2026-11-11Savara Inc.period ending 2026-09-30
  • 2026-11-11Sellas Life Sciences Groupperiod ending 2026-09-30
  • 2026-11-11TScan Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-11Tenax Therapeuticsperiod ending 2026-09-30
  • 2026-11-11TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)period ending 2026-09-30
  • 2026-11-11Unicycive Therapeuticsperiod ending 2026-09-30
  • 2026-11-11XBiotechperiod ending 2026-09-30
  • 2026-11-12Ainos, Inc.period ending 2026-09-30
  • 2026-11-12Aktis Oncology, Inc.period ending 2026-09-30
  • 2026-11-12Alpha Cognition Inc.period ending 2026-09-30
  • 2026-11-12Alumisperiod ending 2026-09-30
  • 2026-11-12Arbutus Biopharmaperiod ending 2026-09-30
  • 2026-11-12Candel Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-12Cellectar Biosciences, Inc.period ending 2026-09-30
  • 2026-11-12Clene Nanomedicineperiod ending 2026-09-30
  • 2026-11-12Cybinperiod ending 2026-09-30
  • 2026-11-12Eikon Therapeuticsperiod ending 2026-09-30
  • 2026-11-12Fate Therapeuticsperiod ending 2026-09-30
  • 2026-11-12Grace Therapeuticsperiod ending 2026-09-30
  • 2026-11-12Immunic, Inc.period ending 2026-09-30
  • 2026-11-12Jade Biosciences, Inc.period ending 2026-09-30
  • 2026-11-12Kodiak Sciences Inc.period ending 2026-09-30
  • 2026-11-12Marker Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-12Moleculinperiod ending 2026-09-30
  • 2026-11-12ORIC Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-12Omeros Corporationperiod ending 2026-09-30
  • 2026-11-12Oncopeptides AB (publ)period ending 2026-09-30
  • 2026-11-12Oramedperiod ending 2026-09-30
  • 2026-11-12Precigen, Incperiod ending 2026-09-30
  • 2026-11-12Protalix BioTherapeutics, Inc.period ending 2026-09-30
  • 2026-11-12Q32 Bioperiod ending 2026-09-30
  • 2026-11-12Sagimet Biosciences Inc.period ending 2026-09-30
  • 2026-11-12Senti Biosciencesperiod ending 2026-09-30
  • 2026-11-12Serodusperiod ending 2026-09-30
  • 2026-11-12Trevi Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-12VistaGen Therapeuticsperiod ending 2026-09-30
  • 2026-11-12Xilio Development, Inc.period ending 2026-09-30
  • 2026-11-13Actinium Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-13Alaunos Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-13Allarity Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-13Arecor Limitedperiod ending 2026-09-30
  • 2026-11-13Celularity Inc.period ending 2026-09-30
  • 2026-11-13Enlivex Therapeuticsperiod ending 2026-09-30
  • 2026-11-13Faeth Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-13GRI Bio, Inc.period ending 2026-09-30
  • 2026-11-13Galectin Therapeutics Inc.period ending 2026-09-30
  • 2026-11-13Genprex, Inc.period ending 2026-09-30
  • 2026-11-13Inhibikase Therapeuticsperiod ending 2026-09-30
  • 2026-11-13Inhibrx Biosciences, Incperiod ending 2026-09-30
  • 2026-11-13Jaguar Healthperiod ending 2026-09-30
  • 2026-11-13MiNK Therapeutics, Inc.period ending 2026-09-30
  • 2026-11-13NRx Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-13Neonc Technologies, Inc.period ending 2026-09-30
  • 2026-11-13Palatin Technologiesperiod ending 2026-09-30
  • 2026-11-13Scholar Rockperiod ending 2026-09-30
  • 2026-11-13TuHURA Biosciencesperiod ending 2026-09-30
  • 2026-11-16Enanta Pharmaceuticals, Inc.period ending 2026-09-30
  • 2026-11-23BioLineRx Ltd.period ending 2026-09-30
  • 2026-11-24Anavex Life Sciencesperiod ending 2026-09-30
  • 2026-11-24Arrowhead Pharmaceuticalsperiod ending 2026-09-30
  • 2026-11-25Lexaria Bioscienceperiod ending 2026-08-31

Educational data tool. Earnings dates cover US-listed companies only; no forward earnings date is sourced for foreign-only listings.